Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis

We evaluated the expression of Prx isoforms in normal tissue, cervical intraepithelial neoplasia, and cervical cancer



Scholarcy highlights

  • Cervical cancer is the second most common cancer among women worldwide, with a half-million new cases and over 270,000 deaths annually
  • Many studies have been conducted on peroxiredoxin I in various kinds of human carcinoma tissues
  • It was reported that expression of peroxiredoxins, especially III, IV and V, is increased in breast malignancy, suggesting the induction of Prxs in response to increased production of reactive oxygen species in carcinomatous tissue
  • In order to monitor the expression levels of the Prx family in cervical cancer, immunoblotting with Prx antibodies were performed with the cervical cancer tissue samples
  • We focused on the four mammalian 2-Cys members, one of two major Prx subfamilies that utilize thioredoxin as the electron donor for antioxidation
  • Prx II and Prx III were highly expressed in high-grade cervical intraepithelial neoplasia and Cx ca, while undetectable or weakly expressed in normal and low-grade CINs, suggesting that they can be used as a tumor marker to predict progression of cervical cancer
  • Understanding the function and biological role of these Prx isoforms may lead to important discoveries on the cellular dysfunction of malignant epithelial cervical cancer, and may be applied in the development of therapeutic agents for patients who have resistance to cancer therapy

Need more features? Save interactive summary cards to your Scholarcy Library.